Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors
Both ATE and VTE incidences seem to be modest in patients with melanoma receiving ICI in both disease settings. Patients with higher BMI and who are prescribed ICI combination therapy might be at increased thrombotic risk.
Authors
- Astrid A.M. van der Veldt (ORCID: https://orcid.org/0000-0003-0446-1907)
- Karlijn de Joode (ORCID: https://orcid.org/0000-0001-5928-2899)
- Daan C.H. van Dorst (ORCID: https://orcid.org/0000-0001-6817-9156)
- R.M. de Waal
- Marieke J. H. A. Kruip (ORCID: https://orcid.org/0000-0002-0265-4871)
- Jorie Versmissen (ORCID: https://orcid.org/0000-0003-0674-7765)
- Esther Oomen‐de Hoop (ORCID: https://orcid.org/0000-0003-2506-3852)
- Sander Bins (ORCID: https://orcid.org/0000-0002-8280-9836)
- Maaike M. Hofman
- Stijn L.W. Koolen (ORCID: https://orcid.org/0000-0002-0973-7530)
- Ron H.J. Mathijssen (ORCID: https://orcid.org/0000-0001-5667-5697)
- Arjen Joosse
Institutions
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1016/j.iotech.2025.101063
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87